Cytek Biosciences (CTKB) Competitors

10x Genomics (NASDAQ:TXG) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, community ranking, media sentiment and dividends.

Is TXG or CTKB more profitable?

Cytek Biosciences has a net margin of -5.05% compared to 10x Genomics' net margin of -29.90%. Cytek Biosciences' return on equity of -2.58% beat 10x Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
10x Genomics	-29.90%	-25.40%	-19.69%
Cytek Biosciences	-5.05%	-2.58%	-2.05%

Does the media favor TXG or CTKB?

In the previous week, 10x Genomics had 15 more articles in the media than Cytek Biosciences. MarketBeat recorded 18 mentions for 10x Genomics and 3 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 0.78 beat 10x Genomics' score of 0.75 indicating that Cytek Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
10x Genomics	10 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytek Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has higher valuation & earnings, TXG or CTKB?

Cytek Biosciences has lower revenue, but higher earnings than 10x Genomics. Cytek Biosciences is trading at a lower price-to-earnings ratio than 10x Genomics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$624.66M	1.78	-$182.63M	-$1.30	-6.98
Cytek Biosciences	$197.05M	1.71	-$12.15M	-$0.09	-29.56

Which has more volatility & risk, TXG or CTKB?

10x Genomics has a beta of 1.94, suggesting that its share price is 94% more volatile than the S&P 500. Comparatively, Cytek Biosciences has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500.

Do insiders and institutionals believe in TXG or CTKB?

84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are owned by institutional investors. 9.4% of 10x Genomics shares are owned by company insiders. Comparatively, 9.6% of Cytek Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Do analysts rate TXG or CTKB?

10x Genomics currently has a consensus target price of $15.81, indicating a potential upside of 74.09%. Cytek Biosciences has a consensus target price of $5.25, indicating a potential upside of 97.37%. Given Cytek Biosciences' higher possible upside, analysts plainly believe Cytek Biosciences is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	1 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.38
Cytek Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Does the MarketBeat Community believe in TXG or CTKB?

10x Genomics received 43 more outperform votes than Cytek Biosciences when rated by MarketBeat users. Likewise, 50.39% of users gave 10x Genomics an outperform vote while only 44.00% of users gave Cytek Biosciences an outperform vote.

Company	Underperform	Outperform
10x Genomics	Outperform Votes 65 50.39%	Underperform Votes 64 49.61%
Cytek Biosciences	Outperform Votes 22 44.00%	Underperform Votes 28 56.00%

Summary

10x Genomics beats Cytek Biosciences on 10 of the 18 factors compared between the two stocks.